Publications: Prof Chloe Orkin

Ring K, Orkin C ( 2024 ) . Long-acting antiretroviral therapy in the context of viral suppression . Current Opinion in HIV and AIDS vol. 20 , ( 1 ) 4 - 10 .

Orkin C, Paparini S, Hayes R ( 2024 ) . Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: results from the anti-sexist, anti-racist, anti-ageist ILANA study . Clinical Infectious Diseases

Palumbo L, Picchio CA, Barbier F, Calderon-Cifuentes A, James J, Lunchenkov N, Nutland W, Owen G et al. ( 2024 ) . Co-creating a Mpox Elimination Campaign in the WHO European Region: The Central Role of Affected Communities . Open Forum Infectious Diseases vol. 11 , ( 10 )

Jackson SS, O’Callaghan S, Ward E, Orkin CM, Clarke MA, Berner AM ( 2024 ) . Rationale and design of the Self-TI Study protocol: a cross-sectional human papillomavirus self-testing pilot study among transgender adults in England . BMJ Open vol. 14 , ( 7 )

Paparini S, Whelan I, Mwendera C, Hayes R, Maatouk I, Lewis R, Nunez MP, Mozalevskis A et al. ( 2024 ) . Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches . Infectious Diseases vol. 56 , ( 8 ) 589 - 605 .

McCabe L, Burns JE, Latifoltojar A, Post FA, Fox J, Pool E, Waters A, Santana B et al. ( 2024 ) . MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV . AIDS vol. 38 , ( 10 ) 1513 - 1522 .

Ring K, Smuk M, Shongwe M, Okonta L, Mackie NE, Ayres S, Barber TJ, Akodu J et al. ( 2024 ) . Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net) . HIV Medicine vol. 25 , ( 10 ) 1125 - 1134 .

Saloniki E-C, Halvorsrud K, Whelan I, Halim N, George R, Orkin C ( 2024 ) . Staff disability data in UK higher education: Evidence from EDI reports . Medical Humanities vol. 50 , ( 3 ) 555 - 560 .

Orkin C, Ring K ( 2024 ) . Implementing long-acting injectable cabotegravir and rilpivirine in Africa . The Lancet Infectious Diseases vol. 24 , ( 10 ) 1060 - 1061 .

Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C et al. ( 2024 ) . Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial . The Lancet HIV vol. 11 , ( 3 ) e156 - e166 .

Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina J-M, Lazzarin A, Maggiolo F et al. ( 2024 ) . Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy . AIDS vol. 38 , ( 7 ) 983 - 991 .

Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F et al. ( 2024 ) . Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT) . EClinicalMedicine vol. 69 ,

Hayes R, Dakin F, Smuk M, Paparini S, Apea V, Dewsnap C, Waters L, Anderson J et al. ( 2024 ) . Cross-sectional survey of sexual health professionals’ experiences and perceptions of the 2022 mpox outbreak in the UK . BMJ Open vol. 14 , ( 1 )

Orkin C ( 2024 ) . Should Human Immunodeficiency Virus Testing Be Replaced With Combined Blood-Borne Virus Testing? . Open Forum Infectious Diseases vol. 11 , ( 2 )

Howe A, Orkin C, Apea V ( 2023 ) . The under-representation of racially minoritised doctors in academic general practice training . BJGP Open vol. 8 , ( 2 )

Orkin C, Molina J-M, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H et al. ( 2023 ) . Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials . The Lancet HIV vol. 11 , ( 2 ) e75 - e85 .

Guaraldi G, Milic J, Cascio M, Mussini C, Martinez E, Levin J, Calzavara D, Mbewe R et al. ( 2023 ) . Ageism: the -ism affecting the lives of older people living with HIV . The Lancet HIV vol. 11 , ( 1 ) e52 - e59 .

Howe A, Wan YI, Gilleece Y, Aebi-Popp K, Dhairyawan R, Bhagani S, Paparini S, Orkin C ( 2023 ) . Gender and ethnicity intersect to reduce participation at a large European hybrid HIV conference . BMJ Leader vol. 8 , ( 3 ) 227 - 233 .

Mitjà O, Paredes R, Cabtree B, Orkin C ( 2023 ) . Classifying necrotising mpox as an AIDS-defining condition . The Lancet vol. 402 , ( 10414 ) 1751 - 1752 .

Wan YI, Smuk M, Pearse RM, Paparini S, Apea VJ, Orkin CM ( 2023 ) . Clinical research in the NHS: a cross-sectional study of research engagement during the monkeypox pandemic . BMJ Leader vol. 7 , ( Suppl 2 )

Cevik M, Orkin C ( 2023 ) . Changing face of mpox . Clinical Microbiology and Infection vol. 29 , ( 12 ) 1485 - 1486 .

Thornhill JP, Gandhi M, Orkin C ( 2023 ) . Mpox: The Reemergence of an Old Disease and Inequities . Annual Review of Medicine vol. 75 , ( 1 ) 159 - 175 .

Shabbir A, Chhetri I, Khambata RS, Parakaw T, Lau C, Aubdool MABN, Massimo G, Dyson N et al. ( 2023 ) . A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study . Trials vol. 24 , ( 1 )

Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, Suñer C, Lemaignen A et al. ( 2023 ) . Mpox in people with past infection or a complete vaccination course: a global case series . The Lancet Infectious Diseases vol. 24 , ( 1 ) 57 - 64 .

Henao-Martínez AF, Orkin CM, Titanji BK, Rodriguez-Morales AJ, Salinas JL, Franco-Paredes C, Tuells J, Chastain DB ( 2023 ) . Hospitalization risk among patients with Mpox infection—a propensity score matched analysis . Therapeutic Advances in Infectious Disease vol. 10 ,

Orkin C, Paparini S, Thornhill JP, Apea V, Mwendera CA, Smuk M, Hayes R, Anderson J ( 2023 ) . SHARING to create knowledge in a crisis . BMJ Leader vol. 7 , ( Suppl 2 )

González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink H-J et al. ( 2023 ) . Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir . Journal of Antimicrobial Chemotherapy vol. 78 , ( 9 ) 2361 - 2365 .

Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, Iser D, Ustianowski A et al. ( 2023 ) . Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study . JHEP Reports vol. 5 , ( 10 )

Bradshaw D, Abramowicz I, Bremner S, Verma S, Gilleece Y, Kirk S, Nelson M, Housman R et al. ( 2023 ) . Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease . PLOS ONE vol. 18 , ( 7 )

Farooq HZ, Apea V, Kasadha B, Ullah S, Hilton-Smith G, Haley A, Scherzer J, Hand J et al. ( 2023 ) . Study protocol: the ILANA study – exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK – a qualitative multiphase longitudinal study design . BMJ Open vol. 13 , ( 7 )

Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y et al. ( 2023 ) . Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure . Clinical Infectious Diseases . vol. 77 , 1423 - 1431 .

Orkin C, Paparini S, Apea V ( 2023 ) . Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK . The Lancet HIV

Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink H-J et al. ( 2023 ) . Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials . EClinicalMedicine vol. 59 ,

Dhairyawan R, Milner A, Thornhill JP, Kwardem L, Matin N, Orkin C, Deane K ( 2023 ) . Experiences of initiating rapid antiretroviral therapy among people newly diagnosed with HIV in East London: a qualitative study . Sexually Transmitted Infections vol. 99 , ( 7 ) 455 - 460 .

Mitjà O, Alemany A, Marks M, Mora JIL, Rodríguez-Aldama JC, Silva MST, Herrera EAC, Crabtree-Ramirez B et al. ( 2023 ) . Mpox in people with advanced HIV infection: a global case series . The Lancet vol. 401 , ( 10380 ) 939 - 949 .

Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter‐Riniker F, Günthard HF, Rockstroh JK et al. ( 2023 ) . Hepatitis delta infection among persons living with HIV in Europe . Liver International vol. 43 , ( 4 ) 819 - 828 .

Ramgopal M, Warupa A, Baumgarten A, Berhe M, Pozniak A, Orkin C, Tiraboschi JM, Hagins D et al. ( 2023 ) . 5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials . HIV MEDICINE . vol. 24 , 33 - 33 .

Orkin C, Koethe JR, Kumar PN, Xu ZJ, Plank RM, Greaves W, Sklar P, Lahoulou R ( 2023 ) . Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen . HIV MEDICINE . vol. 24 , 53 - 54 .

Orkin C ( 2023 ) . Lenacapavir in first-line therapy . The Lancet HIV vol. 10 , ( 1 ) e2 - e3 .

Sax P, Arribas J, Orkin C, Lazzarin A, Pozniak A, Maggiolo F, Stellbrink H-J, Yazdanpanah Y et al. ( 2023 ) . Long-term integrated analysis of B/F/TAF in treatment-naive adults with HIV through five years of follow-up . HIV MEDICINE . vol. 24 , 55 - 56 .

Orkin C, Antinori A, Rockstroh J, Guillen SM, Martorell C, Molina J-M, Lazzarin A, Maggiolo F et al. ( 2023 ) . Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide . HIV MEDICINE . vol. 24 , 21 - 22 .

Hayes R, Mwendera C, Apea V, Paparini S, Orkin C ( 2023 ) . What influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA trial . HIV MEDICINE . vol. 24 , 31 - 32 .

Dimitrakoff J ( 2022 ) . Monkeypox Virus Infection across 16 Countries - April-June 2022 . N Engl J Med vol. 387 , ( 25 )

Dimitrakoff J ( 2022 ) . Monkeypox Virus Infection across 16 Countries — April–June 2022 . New England Journal of Medicine vol. 387 , ( 25 )

Orkin C ( 2022 ) . Reflections and intersections: disability, ‘ableism’ and metamodern leadership . BMJ Leader vol. 7 , ( 2 ) 88 - 90 .

Ramgopal M, Wurapa A, Baumgarten A, Berhe M, Pozniak A, Orkin C, Tiraboschi JM, Hagins DP et al. ( 2022 ) . 1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials . Open Forum Infectious Diseases vol. 9 , ( Supplement_2 )

Waters L, Winston A, Reeves I, Boffito M, Churchill D, Cromarty B, Dunn D, Fink D et al. ( 2022 ) . BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022 . HIV Medicine vol. 23 , ( S5 ) 3 - 115 .

Thornhill J, Orkin C, Cevik M ( 2022 ) . Estimating the global impact of coronavirus disease 2019 on people living with HIV . Current Opinion in Infectious Diseases vol. 36 , ( 1 ) 20 - 25 .

Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, Galliez RM, Garlin AB et al. ( 2022 ) . Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series . The Lancet vol. 400 , ( 10367 ) 1953 - 1965 .

Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe J-J, Marks M, Orkin CM ( 2022 ) . Monkeypox . The Lancet vol. 401 , ( 10370 ) 60 - 74 .

Paparini S, Whitacre R, Smuk M, Thornhill J, Mwendera C, Strachan S, Nutland W, Orkin C ( 2022 ) . Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency . HIV Medicine vol. 24 , ( 5 ) 544 - 557 .

Gibas KM, Kelly SG, Arribas JR, Cahn P, Orkin C, Daar ES, Sax PE, Taiwo BO ( 2022 ) . Two-drug regimens for HIV treatment . The Lancet HIV vol. 9 , ( 12 ) e868 - e883 .

Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F et al. ( 2022 ) . Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial . Clinical Infectious Diseases vol. 76 , ( 5 ) 861 - 870 .

Mocroft A, Geressu A, Beguelin C, Llibre JM, Lazarus JV, Tomazic J, Smidt J, Parczewski M et al. ( 2022 ) . The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe . AIDS vol. 37 , ( 1 ) 91 - 103 .

Mussini C, Guaraldi G, Orkin C ( 2022 ) . Monkeypox vaccination—an opportunity for HIV prevention . The Lancet HIV vol. 9 , ( 11 ) e741 - e742 .

Drysdale K, Cutino-Moguel M-T, Dakshina S, Dhairyawan R, Moloney J, Orkin PC, Sarner L, Ullah S et al. ( 2022 ) . P76 Going, going, gone? Routine emergency department hepatitis C testing can drive elimination efforts. Data from a single UK urban centre show sustained significant decreases in hepatitis C viraemia over time . Conference: Abstractsa89 - a89 .

Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C et al. ( 2022 ) . Observational cohort study of rilpivirine (RPV) utilization in Europe . AIDS Research and Therapy vol. 19 , ( 1 )

Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A et al. ( 2022 ) . Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 . New England Journal of Medicine vol. 387 , ( 8 ) 679 - 691 .

Boffito M, Scarsi K, Orkin C ( 2022 ) . Editorial: Is it time to implement injectable antiretroviral treatments globally? . Current Opinion in HIV and AIDS vol. 17 , ( 3 ) 119 - 120 .

Orkin C, Cahn P, Castagna A, Emu B, Harrigan PR, Kuritzkes DR, Nelson M, Schapiro J ( 2022 ) . Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV . HIV Medicine vol. 23 , ( 9 ) 936 - 946 .

Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2022 ) . Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London . Scientific Reports vol. 12 , ( 1 )

Orkin C, Apea V ( 2022 ) . International Women's Day—how can I help? . The Lancet HIV vol. 9 , ( 4 ) e228 - e229 .

Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M et al. ( 2022 ) . A highly virulent variant of HIV-1 circulating in the Netherlands . Science vol. 375 , ( 6580 ) 540 - 545 .

Wohl D, Pozniak A, Workowski K, Haggins D, Daar E, Orkin C, Koenig E, Mounzer K et al. ( 2022 ) . B/F/TAF 5-year outcomes in treatment-naive adults . HIV MEDICINE . vol. 23 , 29 - 30 .

Daar E, Orkin C, Sax P, Koenig E, Clarke A, Baumgarten A, Brinson C, Huang H et al. ( 2022 ) . Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years . HIV MEDICINE . vol. 23 , 12 - 12 .

Paparini S, Strachan S, Thornhill J, Nutland W, Mwendera C, Orkin C ( 2022 ) . Including women in the public health response to the monkeypox (MPXV) outbreak in the UK: findings from a rapid response, co-produced survey . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 19 - 19 .

Lathouwers E, Baugh B, Vanveggel S, Van Landuyt E, Opsomer M, Orkin C, Eron J ( 2022 ) . Long-term efficacy and resistance analyses of D/C/F/TAF in the phase III AMBER and EMERALD studies: post 96-week data . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 195 - 196 .

Orkin C, Antinori A, Rockstroh J, Guillen SM, Martorell C, Molina J, Lazzarin A, Maggiolo F et al. ( 2022 ) . Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 88 - 89 .

Paparini S, Thornhill J, Mwendera C, Strachan S, Whitacre R, Nutland W, Orkin C ( 2022 ) . Perceptions and understandings of media and public health messaging about the monkeypox outbreak in the UK: findings from a rapid response, co-produced survey . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 18 - 19 .

Bradshaw D, Abramowicz I, Bremner S, Verma S, Gilleece Y, Kirk S, Nelson M, Housman R et al. ( 2022 ) . Results of Hepmarc: a 96-week feasibility trial of add-on maraviroc in people with well-controlled HIV and NAFLD . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 147 - 148 .

Iwuji C, Waters L, Milinkovic A, Orkin C, Perry N, Dailey N, To Y, Bremner S et al. ( 2022 ) . Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance: a phase IV randomised, open-label pilot study (PIBIK study) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 25 , 89 - 90 .

Dhairyawan R, Milner A, Thornhill J, Kwardem L, Matin N, Orkin C, Deane K ( 2022 ) . The acceptability of offering rapid antiretroviral therapy to people living with HIV in east London: a qualitative study . HIV MEDICINE . vol. 23 , 13 - 14 .

Thornhill J, Orkin C ( 2021 ) . Long-acting injectable HIV therapies: the next frontier . Current Opinion in Infectious Diseases vol. 34 , ( 1 ) 8 - 15 .

Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink H et al. ( 2021 ) . HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe . HIV Medicine vol. 23 , ( 6 ) 684 - 692 .

Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van Bremen K, Beniowski M, Mikhalik J et al. ( 2021 ) . The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study . HIV Medicine vol. 23 , ( 6 ) 585 - 598 .

Campbell L, Ibrahim F, Barbini B, Samarawickrama A, Orkin C, Fox J, Waters L, Gilleece Y et al. ( 2021 ) . Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir . HIV Medicine vol. 23 , ( 4 ) 362 - 370 .

Daar E, Orkin C, Sax P, Stephens JL, Koenig E, Clarke A, Baumgarten A, Brinson C et al. ( 2021 ) . 69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks . Open Forum Infectious Diseases vol. 8 , ( Supplement_1 ) 46 - 46 .

Okhai H, Tariq S, Burns F, Gilleece Y, Dhairyawan R, Hill T, Peters H, Thorne C et al. ( 2021 ) . Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study . The Lancet HIV vol. 8 , ( 12 ) e747 - e754 .

Fursa O, Mocroft A, Lazarus JV, Amele S, Lundgren J, Matulionyte R, Rasmussen LD, Rockstroh JK et al. ( 2021 ) . The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences . AIDS vol. 36 , ( 3 ) 423 - 435 .

Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink H-J, Belonosova E, DeMoor R, Griffith S et al. ( 2021 ) . Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study . The Lancet HIV vol. 8 , ( 11 ) e668 - e678 .

Lee MJ, Snell LB, Douthwaite ST, Fidler S, Fitzgerald N, Goodwin L, Hamzah L, Kulasegaram R et al. ( 2021 ) . Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study) . HIV Medicine vol. 23 , ( 2 ) 121 - 133 .

Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y et al. ( 2021 ) . Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 88 , ( 4 ) 393 - 398 .

Wan YI, Robbins AJ, Apea VJ, Orkin CM, Pearse R, Puthucheary ZA, Prowle JR ( 2021 ) . Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data . EClinicalMedicine101077 - 101077 .

Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2021 ) . Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London . medrxiv

González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink H-J et al. ( 2021 ) . Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV . Journal of Antimicrobial Chemotherapy vol. 76 , ( 9 ) 2380 - 2393 .

Pelchen-Matthews A, Borges ÁH, Reekie J, Rasmussen LD, Wiese L, Weber J, Pradier C, Degen O et al. ( 2021 ) . Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 87 , ( 2 ) 806 - 817 .

Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H et al. ( 2021 ) . Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials . Clinical Infectious Diseases vol. 73 , ( 8 ) 1440 - 1451 .

Asad H, Collins I, Goodall R, Crichton S, Hill T, Doerholt K, Foster C, Lyall H et al. ( 2021 ) . Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK . HIV Medicine vol. 22 , ( 8 ) 631 - 640 .

Zenner D ( 2021 ) . The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London . International Journal of Tuberculosis and Lung Disease

Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG et al. ( 2021 ) . Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study . The Lancet HIV vol. 8 , ( 4 ) e185 - e196 .

Penfold R, Arnold-Forster A, Orkin C ( 2021 ) . Redressing Gender Imbalance in Leadership in Academic Medicine . Academic Medicine vol. 96 , ( 4 )

Wan YI, Bien Z, Apea VJ, Orkin CM, Dhairyawan R, Kirwan CJ, Pearse RM, Puthucheary ZA et al. ( 2021 ) . Acute Kidney Injury in COVID-19: multicentre prospective analysis of registry data . Clinical Kidney Journalsfab071- - sfab071- .

Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d'Arminio Monforte A, Reiss P et al. ( 2021 ) . Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study . Annals of Internal Medicine vol. 174 , ( 6 ) 768 - 776 .

Thornhill J, Orkin C ( 2021 ) . Long-acting injectable HIV therapies: the next frontier: Republication . Current Opinion in HIV and AIDS vol. 16 , ( 2 ) 98 - 105 .

Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2021 ) . Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study . BMJ Open vol. 11 , ( 1 ) e042140 - e042140 .

Cevik M, Haque SA, Manne-Goehler J, Kuppalli K, Sax PE, Majumder MS, Orkin C ( 2021 ) . Gender disparities in coronavirus disease 2019 clinical trial leadership . Clinical Microbiology and Infection vol. 27 , ( 7 ) 1007 - 1010 .

Workowski K, Orkin C, Sax P, Hagins D, Koenig E, Stephens J, Gupta S, Huang H et al. ( 2021 ) . Four year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive adults . HIV MEDICINE . vol. 22 , 32 - 33 .

El Bouzidi K, Tostevin A, Pozniak A, Asboe D, Churchill D, Phillips A, Orkin C, Winston A et al. ( 2021 ) . Integrase inhibitor drug resistance in clinical practice in the United Kingdom . HIV MEDICINE . vol. 22 , 6 - 6 .

Orkin C, Oka S, Philibert P ( 2021 ) . Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study (vol 8, pg e185, 2021) . LANCET HIV vol. 8 , ( 12 ) E734 - E734 .

Pozniak A, Maggiolo F, Podzamczer D, Yazdanpanah Y, Gupta S, Esser S, Mounzer K, Grossberg R et al. ( 2021 ) . Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF . HIV MEDICINE . vol. 22 , 125 - 125 .

Pett S, McCabe L, Latifoltojar A, Post F, Fox J, Burns J, Pool E, Waters A et al. ( 2021 ) . Results of MAVMET, a multi-centre, open-label, 48-week randomised controlled trial of maraviroc with or without metformin for the treatment of non-alcoholic fatty liver disease in HIV-positive virologically suppressed adults . HIV MEDICINE . vol. 22 , 43 - 45 .

D'Amico R, Orkin C, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al. ( 2021 ) . Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results . INFECTION . vol. 49 , S7 - S7 .

Molina JM, Orkin C, Cahn P, Lombaard J, Supparatpinyo K, Campbell H, Wan H, Teal V et al. ( 2021 ) . Safety and efficacy of doravirine in treatment-naive adults with HIV-1: 4 years of experience from the DRIVE-FORWARD and DRIVE-AHEAD clinical trials . HIV MEDICINE . vol. 22 , 29 - 30 .

Patel P, D'Amico R, Thiagarajah S, Wu S, Elliot E, Polli JW, Upadhyay O, Van Solingen-Ristea R et al. ( 2021 ) . WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS . SEXUAL HEALTH . vol. 18 , VI - VI .

Orkin C, D'Amico R, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al. ( 2021 ) . Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 24 , 22 - 22 .

Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ et al. ( 2020 ) . Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial . Clinical Infectious Diseases vol. 73 , ( 1 ) 33 - 42 .

Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, Rassool M, Rodgers A et al. ( 2020 ) . Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine . AIDS vol. 35 , ( 5 ) 759 - 767 .

Orkin C, Elion R, Thompson M, Rockstroh JK, Bognar FA, Xu ZJ, Hwang C, Sklar P et al. ( 2020 ) . Changes in weight and BMI with first-line doravirine-based therapy . AIDS vol. 35 , ( 1 ) 91 - 99 .

Mariot P, Orkin C, Elion R, Thompson M, Rockstroh J, Xu Z, Martin E, Hwang C et al. ( 2020 ) . Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral . Infectious Diseases Now vol. 50 , ( 6 )

Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Hernández-Mora MG, Pokrovsky V, Girard P-M et al. ( 2020 ) . Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 85 , ( 4 ) 498 - 506 .

Garvey L, Cooke G, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al. ( 2020 ) . AS039 Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK? . Journal of Hepatology vol. 73 , s32 - s33 .

Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F et al. ( 2020 ) . Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease . Journal of Antimicrobial Chemotherapy vol. 75 , ( 11 ) 3334 - 3343 .

Ibrahim F, Campbell L, Bailey A, Stockwell S, Waters L, Orkin C, Johnson M, Gompels M et al. ( 2020 ) . Estimated glomerular filtration rate slopes on tenofovir alafenamide . HIV Medicine vol. 21 , ( 9 ) 607 - 612 .

Iwuji CC, Churchill D, Bremner S, Perry N, To Y, Lambert D, Bruce C, Waters L et al. ( 2020 ) . A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial . BMC Infectious Diseases vol. 20 , ( 1 )

van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al. ( 2020 ) . Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 85 , ( 3 ) 325 - 330 .

Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al. ( 2020 ) . Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection . Hepatology vol. 72 , ( 1 ) 7 - 18 .

Apea V, Wan Y, Dhairyawan R, Puthucheary Z, Pearse R, Orkin C, Prowle J ( 2020 ) . Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study . medrxiv

Cevik M, Orkin C, Sax PE ( 2020 ) . Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases . Open Forum Infectious Diseases vol. 7 , ( 6 )

Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink H-J et al. ( 2020 ) . Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials . The Lancet HIV vol. 7 , ( 6 ) e389 - e400 .

Wan Y, Apea V, Dhairyawan R, Orkin C, Pearse RM, Prowle JR ( 2020 ) . ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London .

Orkin C, Goddard SL ( 2020 ) . Enrolling pregnant women with HIV into clinical trials . The Lancet HIV vol. 7 , ( 5 ) e302 - e303 .

Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al. ( 2020 ) . Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients . AIDS vol. 34 , ( 5 ) 707 - 718 .

Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al. ( 2020 ) . Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom? . Clinical Infectious Diseases vol. 72 , ( 2 ) 233 - 238 .

Gupta N, Gilleece Y, Orkin C ( 2020 ) . Implementing U=U in clinical practice: results of a British HIV association members survey . Sexually Transmitted Infections vol. 97 , ( 8 ) 619 - 620 .

Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S et al. ( 2020 ) . Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection . New England Journal of Medicine vol. 382 , ( 12 ) 1124 - 1135 .

Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Tostevin A, Hill T et al. ( 2020 ) . Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation . HIV Medicine vol. 21 , ( 5 ) 309 - 321 .

Orkin C, Molina J-M, Yazdanpanah Y, Anania CC, DeJesus E, Eron J, Klopfer S, Grandhi A et al. ( 2020 ) . Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 15 - 16 .

Orkin C, Molina J, Yazdanpanah Y, Chahin Anania C, DeJesus E, Eron J, Klopfer S, Grandhi A et al. ( 2020 ) . Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 51 - 52 .

Garvey L, Cooke G, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al. ( 2020 ) . Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK? . JOURNAL OF HEPATOLOGY . vol. 73 , S32 - S33 .

Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Liu YP, Wei X et al. ( 2020 ) . Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide versus comparators in cis-women and girls (living with HIV): an analysis of five clinical trials . HIV MEDICINE . vol. 21 , 18 - 19 .

Parry S, Williamson M, Orkin C, Matin N, Dhairyawan R ( 2020 ) . HIV-related admissions to a London specialist unit: who, what and why? . HIV MEDICINE . vol. 21 , 54 - 54 .

Bradshaw D, Abramowicz I, Bremner S, Gilleece Y, Fedele S, Kirk S, Clarke C, Williams S et al. ( 2020 ) . Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 76 - 77 .

Samarawickrama A, Hamzah L, Ibrahim F, Ainsworth J, Fox J, Gilleece Y, Hemat N, Johnson M et al. ( 2020 ) . Increase in bone mineral density and weight in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG . HIV MEDICINE . vol. 21 , 13 - 13 .

Orkin C, Oka S, Philibert P, Brinson C, Bassa AC, Gusev D, Degen O, Gonzalez Garcia J et al. ( 2020 ) . Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results . HIV MEDICINE . vol. 21 , 14 - 14 .

Orkin C, Sax P, Arribas J, Gupta S, Martorell C, Stephens J, Stellbrink H-J, DeJesus E et al. ( 2020 ) . Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults . HIV MEDICINE . vol. 21 , 18 - 18 .

Orkin C ( 2020 ) . Novel ART compounds . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 10 - 10 .

D'Amico R, Orkin C, Bernal Morell E, Tan D, Katner H, Singh Y, Stellbrink H, Belonosova E et al. ( 2020 ) . Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 10 - 12 .

Chounta V, Wu S, Upadhyay O, Griffith S, Harrington C, Orkin C, Swindells S, Spreen W et al. ( 2020 ) . Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 24 - 24 .

Andreatta K, Acosta R, D'Antoni M, Porter D, Chang S, Martin R, Willkom M, McNicholl I et al. ( 2020 ) . Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide . HIV MEDICINE . vol. 21 , 18 - 18 .

Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al. ( 2019 ) . Impact of early antiretroviral treatment on sexual behaviour . AIDS vol. 33 , ( 15 ) 2337 - 2350 .

Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al. ( 2019 ) . Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison . AIDS vol. 33 , ( 15 ) 2337 - 2350 .

( 2019 ) . Erratum . Clinical Infectious Diseases vol. 70 , ( 2 ) 360 - 360 .

Cevik M, Orkin C ( 2019 ) . Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents . Expert Opinion on Investigational Drugs vol. 28 , ( 12 ) 1021 - 1024 .

( 2019 ) . EACS 2019 – Abstract Book . HIV Medicine . vol. 20 , 3 - 316 .

Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT et al. ( 2019 ) . Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV . Journal of Virus Eradication vol. 5 , ( 4 ) 204 - 211 .

Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A et al. ( 2019 ) . Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe . AIDS vol. 33 , ( 13 ) 2013 - 2024 .

Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E et al. ( 2019 ) . Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials . AIDS Research and Human Retroviruses vol. 36 , ( 1 ) 48 - 57 .

Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK et al. ( 2019 ) . Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials . Clinical Infectious Diseases vol. 71 , ( 6 ) 1379 - 1389 .

Huhn GD, Eron JJ, Girard P-M, Orkin C, Molina J-M, DeJesus E, Petrovic R, Luo D et al. ( 2019 ) . Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study . AIDS Research and Therapy vol. 16 , ( 1 )

Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al. ( 2019 ) . Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies . The Lancet HIV vol. 6 , ( 9 ) e576 - e587 .

Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al. ( 2019 ) . Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016 . Eurosurveillance vol. 24 , ( 27 )

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V et al. ( 2019 ) . Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 . Antiviral Research vol. 170 ,

Orkin C ( 2019 ) . Does less equal more yet? . The Lancet HIV vol. 6 , ( 7 ) e412 - e413 .

Thompson M, Orkin C, Molina J-M, Sax P, Cahn P, Squires K, Xu X, Rodgers A et al. ( 2019 ) . Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis . Clinical Infectious Diseases vol. 70 , ( 7 ) 1336 - 1343 .

Orkin C, Molina J-M, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G et al. ( 2019 ) . Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis . Clinical Infectious Diseases vol. 70 , ( 7 ) 1344 - 1352 .

Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink H-J et al. ( 2019 ) . Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials . AIDS vol. 33 , ( 9 ) 1455 - 1465 .

Cullen L, Grenfell P, Rodger A, Orkin C, Mandal S, Rhodes T ( 2019 ) . ‘Just another vial…’: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK . BMJ Open vol. 9 , ( 4 )

Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y et al. ( 2019 ) . Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 81 , ( 4 ) 463 - 472 .

Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al. ( 2019 ) . THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection . Journal of Hepatology . vol. 70 ,

Martin EA, Hwang C, Orkin C ( 2019 ) . Reply to Lanzafame et al . Clinical Infectious Diseases vol. 69 , ( 10 ) 1832 - 1833 .

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard J et al. ( 2019 ) . Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA . HIV Medicine vol. 20 , ( 4 ) 264 - 273 .

Finnerty F, Azad Y, Orkin C ( 2019 ) . Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services . The Lancet HIV vol. 6 , ( 2 )

Gossez M, Martin GE, Pace M, Ramjee G, Premraj A, Kaleebu P, Rees H, Inshaw J et al. ( 2019 ) . Virological remission after antiretroviral therapy interruption in female African HIV seroconverters . AIDS vol. 33 , ( 2 ) 185 - 197 .

Podzamczer D, Stellbrink H-J, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. ( 2019 ) . B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results . HIV MEDICINE . vol. 20 , 18 - 18 .

Van Wyk J, Orkin C, Rubio-Garcia R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al. ( 2019 ) . Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies . HIV MEDICINE . vol. 20 , 18 - 19 .

Orkin C, Elion R, Thompson M, Rockstroh J, Xu ZJ, Martin EA, Hwang C, Sklar P et al. ( 2019 ) . Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1 . HIV MEDICINE . vol. 20 , 7 - 8 .

Orkin C, Kityo C, Koenig E, Natukunda E, Ajana F, Gandhi-Patel B, Liu Y, Wei L et al. ( 2019 ) . Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials . HIV MEDICINE . vol. 20 , 22 - 22 .

Orkin C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, Overton ET, Girard P-M, Oka S, D'Amico R et al. ( 2019 ) . Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results . HIV MEDICINE . vol. 20 , 6 - 7 .

Orkin C, Sax PE, Arribas J, Gupta S, Martorell C, Stephens JL, Stellbrink H-J, Dejesus E et al. ( 2019 ) . Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults . HIV MEDICINE . vol. 20 , 94 - 95 .

Stellbrink H-J, Post FA, Podzamczer D, Arribas J, Cua E, Molina J-M, Orkin C, Rockstroh JK et al. ( 2019 ) . Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older . HIV MEDICINE . vol. 20 , 138 - 138 .

Orkin C, Porteiro N, Berhe M, Dretler R, Viciana P, Tseng Y, Oprea C, Johnson M et al. ( 2019 ) . Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies . Journal of Infection and Public Health . vol. 12 ,

Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C et al. ( 2018 ) . Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance . Journal of Antimicrobial Chemotherapy vol. 74 , ( 3 ) 746 - 753 .

Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS et al. ( 2018 ) . Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction . Clinical Infectious Diseases vol. 69 , ( 7 ) 1136 - 1143 .

Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S, Lathouwers E, Hufkens V et al. ( 2018 ) . 1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s65 - s65 .

Rockstroh JK, Bhagani SR, Orkin C, Soto-Malave R, Lacombe K, Zhang Z, Wang S, Mensa F et al. ( 2018 ) . 1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s569 - s570 .

Thompson M, Orkin C, Molina J-M, Gatell J, Sax P, Cahn P, Squires K, Zhou Y et al. ( 2018 ) . 543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s201 - s202 .

Orkin C, Squires K, Molina J-M, Sax P, Wong W, Sussmann O, Lin G, Kumar S et al. ( 2018 ) . LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s759 - s759 .

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung C-C, Rockstroh JK et al. ( 2018 ) . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials . The Lancet vol. 393 , ( 10167 ) 143 - 155 .

Orkin C, Squires KE, Molina J-M, Sax PE, Wong W-W, Sussmann O, Kaplan R, Lupinacci L et al. ( 2018 ) . Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial . Clinical Infectious Diseases vol. 68 , ( 4 ) 535 - 544 .

Hagins D, Orkin C, Daar E, Mills A, Brinson C, DeJesus E, Post F, Morales‐Ramirez J et al. ( 2018 ) . Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials . HIV Medicine vol. 19 , ( 10 ) 724 - 733 .

Vazquez ME, Rockstroh J, Lacombe K, Orkin C, Luetkemeyer A, Wyles D, Malave RS, Shermanl KE et al. ( 2018 ) . Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study . International Journal of Infectious Diseases vol. 73 ,

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA et al. ( 2018 ) . Chronic Kidney Disease Risk in African and Caribbean Populations With HIV . The Journal of Infectious Diseases vol. 218 , ( 11 ) 1767 - 1772 .

Eron JJ, Orkin C, Gallant J, Molina J-M, Negredo E, Antinori A, Mills A, Reynes J et al. ( 2018 ) . A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients . AIDS vol. 32 , ( 11 ) 1431 - 1442 .

Cevik M, Orkin C ( 2018 ) . Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate . Current Opinion in HIV and AIDS vol. 13 , ( 4 ) 315 - 319 .

Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A et al. ( 2018 ) . Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16–18 May 2018, Marseille, France: from HIV and comorbidities to global health . Journal of Virus Eradication vol. 4 , ( 3 ) 196 - 207 .

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E et al. ( 2018 ) . Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study . Clinical Infectious Diseases vol. 68 , ( 4 ) 597 - 606 .

Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA, Committee CSS et al. ( 2018 ) . A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study . The Lancet HIV vol. 5 , ( 6 ) e301 - e308 .

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL et al. ( 2018 ) . Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection . Journal of Viral Hepatitis vol. 25 , ( 10 ) 1180 - 1188 .

Cresswell F, Ellis J, Hartley J, Sabin C, Orkin C, Churchill ( 2018 ) . A systematic review of risk of HIV transmission through biting or spitting: implications for policy . HIV Medicine vol. 19 , ( 8 ) 532 - 540 .

Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C ( 2018 ) . Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department – uncovering the iceberg? . Epidemiology and Infection vol. 146 , ( 8 ) 1026 - 1035 .

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C et al. ( 2018 ) . Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data . AIDS Research and Therapy vol. 15 , ( 1 )

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R et al. ( 2018 ) . Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study . Clinical Infectious Diseases vol. 67 , ( 7 ) 1010 - 1017 .

Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O’Shea S, Delpech V et al. ( 2018 ) . Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control . The Journal of Infectious Diseases vol. 217 , ( 10 ) 1522 - 1529 .

Santos, Cozzi‐Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al. ( 2018 ) . Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe . HIV Medicine vol. 19 , ( 5 ) 324 - 338 .

Cresswell F, Ellis J, Hartley J, Sabin C, Brook G, Orkin C, Churchill D ( 2018 ) . A systematic review of risk of HIV transmission through biting or spitting: implications for policy . HIV MEDICINE . vol. 19 , S43 - S43 .

Podzamczer D, Stellbrink H, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. ( 2018 ) . B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,

Orkin C, Eron J, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al. ( 2018 ) . Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,

Krutikov M, Parry S, Drury L, Matin N, Orkin C ( 2018 ) . HIV-related medical admissions to an HIV specialist inpatient unit: quality standards and outcomes . HIV MEDICINE . vol. 19 , S102 - S103 .

Orkin C, Lampe F, Izambert C, Waters L ( 2018 ) . Mental health and HIV: what we all need to know . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,

Orkin C, Libre J, Kahl L, Blair E, Wynne B, Curtis L, Angelis K, Shah R et al. ( 2018 ) . Renal, Inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies . HIV MEDICINE . vol. 19 , S17 - S17 .

Orkin C, Khuong-Josses M-A, Lutz T, Baker D, Rubio R, Blair E, Kahl L, Angelis K et al. ( 2018 ) . Safety and efficacy of DTG plus RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location . HIV MEDICINE . vol. 19 , S28 - S29 .

Martinello M, Cerrone M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K et al. ( 2018 ) . TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection . HIV MEDICINE . vol. 19 , S151 - S152 .

Orkin C, Molina J-M, Gallant J, Negredo E, Gathe J, Eron J, van Landuyt E, Lathouwers E et al. ( 2018 ) . Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults . HIV MEDICINE . vol. 19 , S32 - S32 .

Gallant J, Orkin C, Molina J-M, Negredo E, Antinori A, Mills A, Eron J, Reynes J et al. ( 2018 ) . Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) . HIV MEDICINE . vol. 19 , S32 - S32 .

Roen A, Laut K, Pelchen‐Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, Monforte AD et al. ( 2017 ) . Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort . HIV Medicine vol. 19 , ( 4 ) 252 - 260 .

Orkin C, Molina J-M, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E et al. ( 2017 ) . Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial . The Lancet HIV vol. 5 , ( 1 ) e23 - e34 .

Cozzi‐Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al. ( 2017 ) . Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens . HIV Medicine vol. 19 , ( 2 ) 102 - 117 .

Orkin C, Molina J-M, Gallant J, Negredo E, Gathe J, Eron J, Van Landuyt E, Lathouwers E et al. ( 2017 ) . Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults . Open Forum Infectious Diseases vol. 4 , ( suppl_1 ) s737 - s738 .

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al. ( 2017 ) . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial . The Lancet vol. 390 , ( 10107 ) 2063 - 2072 .

Shepherd L, Borges Á, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al. ( 2017 ) . The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people . HIV Medicine vol. 19 , ( 2 ) 90 - 101 .

Gourlay A, Fox J, Gafos M, Fidler S, Nwokolo N, Clarke A, Gilson R, Orkin C et al. ( 2017 ) . A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England . BMJ Open vol. 7 , ( 8 )

Orkin C, Llibre J, Gallien S, Antinori A, Behrens G, Carr A ( 2017 ) . Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence . HIV Medicine vol. 19 , ( 1 ) 18 - 32 .

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR et al. ( 2017 ) . Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 . Open Forum Infectious Diseases vol. 4 , ( 3 )

Pasvol TJ, Orkin C ( 2017 ) . Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: a retrospective analysis of sexual health screening in East London . Sexually Transmitted Infections vol. 93 , ( 5 )

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A et al. ( 2017 ) . Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study . The Lancet HIV vol. 4 , ( 12 ) e536 - e546 .

Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K et al. ( 2017 ) . Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study . Antiviral Therapy vol. 23 , ( 5 ) 405 - 413 .

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J et al. ( 2017 ) . Brief Report . JAIDS Journal of Acquired Immune Deficiency Syndromes . vol. 75 , 226 - 231 .

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A et al. ( 2017 ) . Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study . The Lancet HIV vol. 4 , ( 7 ) e295 - e302 .

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell A et al. ( 2017 ) . A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada . HIV Medicine vol. 18 , ( 9 ) 655 - 666 .

Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C et al. ( 2017 ) . An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs . Journal of Antimicrobial Chemotherapy vol. 72 , ( 7 ) 2075 - 2082 .

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B et al. ( 2017 ) . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study . The Lancet HIV vol. 4 , ( 5 ) e195 - e204 .

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink H-J, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al. ( 2017 ) . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort . Clinical Infectious Diseases vol. 64 , ( 10 ) 1413 - 1421 .

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al. ( 2017 ) . A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48 . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 20 , 103 - 104 .

Rockstroh J, Lacombe K, Viani R, Orkin C, Wyles D, Luetkemeyer A, Soto-Malave R, Flisiak R et al. ( 2017 ) . Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 20 , 13 - 13 .

Molina J-M, Gallant J, Orkin C, Negredo E, Bhatti L, Gathe J, Van Landuyt E, Lathouwers E et al. ( 2017 ) . Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 20 , 28 - 28 .

Squires KE, Molina J-M, Sax PE, Wong W-W, Orkin C, Sussmann O, Tutu D, Lupinacci L et al. ( 2017 ) . Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naive adults with HIV-1 infection: Week 48 results of the Phase 3 DRIVE-AHEAD study . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 20 , 110 - + .

Rockstroh J, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer A, Soto-Malave R, Flisiak R et al. ( 2017 ) . LBP-522 Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study . Journal of Hepatology vol. 66 , ( 1 ) s102 - s103 .

Orkin C ( 2017 ) . Protease inhibitors in anti-retroviral therapy: past, present and future . INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS . vol. 50 , S14 - S14 .

McNulty M, Orkin C, Smith C, Marshall N, Swaden L, Burns F ( 2017 ) . Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT) . HIV MEDICINE . vol. 18 , 17 - 18 .

Parry S, Ullah S, Foster G, Ahmad K, Tong W, Orkin C, Balasegaram S, Bundle N et al. ( 2017 ) . Routine blood-borne virus testing for HIV, hepatitis B and hepatitis C in the emergency department: the 'new normal'? . HIV MEDICINE . vol. 18 , 5 - 6 .

Martinello M, Bhagani S, Gane EJ, Orkin C, Cooke G, Kulasegaram R, Shaw D, Hellard M et al. ( 2017 ) . Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study . HEPATOLOGY . vol. 66 , 574A - 575A .

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. ( 2017 ) . Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks . HIV MEDICINE . vol. 18 , 21 - 21 .

Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ et al. ( 2016 ) . Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy . AIDS vol. 30 , ( 17 ) 2617 - 2624 .

Fauci A, Hill A, Bekker L, Montaner J, Lundgren J, Rojo P, Laut KG, Shepherd L et al. ( 2016 ) . International Congress of Drug Therapy in HIV Infection 23‐26 October 2016, Glasgow, UK . Journal of the International AIDS Society vol. 19 , ( 8Suppl 7 )

Dhairyawan R, O'Connell R, Flanagan S, Wallis E, Orkin C ( 2016 ) . Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: the ‘Going Viral’ campaign . Sexually Transmitted Infections vol. 92 , ( 7 )

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D et al. ( 2016 ) . Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes . Medicine vol. 95 , ( 41 )

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K et al. ( 2016 ) . Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression . Medicine vol. 95 , ( 40 )

Bouzidi KE, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A et al. ( 2016 ) . HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK . Journal of Antimicrobial Chemotherapy vol. 71 , ( 12 ) 3487 - 3494 .

Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S et al. ( 2016 ) . British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 . HIV Medicine vol. 17 , ( S4 ) s2 - s104 .

Howarth A, Burns F, Apea V, Jose S, Hill T, Delpech, Evans A, Mercer C et al. ( 2016 ) . Development and application of a new measure of engagement in out‐patient HIV care . HIV Medicine vol. 18 , ( 4 ) 267 - 274 .

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A et al. ( 2016 ) . Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom . HIV Medicine vol. 18 , ( 3 ) 204 - 213 .

Ericsen A, Lauck M, Mohns M, Dinapoli S, Mutschler J, Greene J, Weinfurter J, Lehrer‐Brey G et al. ( 2016 ) . Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa . Journal of the International AIDS Society vol. 19 , ( 6 Suppl 5 )

Pasvol T, Khan P, Thiagarajan A, Dakshina S, Sarner L, Orkin C ( 2016 ) . O028 Low proportion of men who have sex with men (MSM) tested for hepatitis C despite high prevalence in 2 genito-urinary medicine (GUM) clinics . Sexually Transmitted Infections vol. 92 , ( Suppl 1 ) a11.1 - a1a11 .

Orkin C, Rjinders B, Stephan C, McKellar M, Kiertiburanakul S, Arribas J, Murphy D, Bloch M et al. ( 2016 ) . P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults . Sexually Transmitted Infections . vol. 92 , a34.1 - a3a34 .

( 2016 ) . Predicting virological decay in patients starting combination antiretroviral therapy . AIDS vol. 30 , ( 11 ) 1817 - 1827 .

Orkin C, Jeffery-Smith A, Foster GR, Tong CYW ( 2016 ) . Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women? . BMJ Open vol. 6 , ( 5 ) e010661 - e010661 .

White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D et al. ( 2016 ) . No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom . The Journal of Infectious Diseases vol. 214 , ( 9 ) 1302 - 1308 .

Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A et al. ( 2016 ) . Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial . Clinical Infectious Diseases vol. 63 , ( 2 ) 257 - 264 .

Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al. ( 2016 ) . Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign . HIV Medicine vol. 17 , ( 3 ) 222 - 230 .

Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J et al. ( 2016 ) . Infection‐related and ‐unrelated malignancies, HIV and the aging population . HIV Medicine vol. 17 , ( 8 ) 590 - 600 .

Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T et al. ( 2016 ) . Clinical characteristics and outcomes of HIV-associated immune complex kidney disease . Nephrology Dialysis Transplantation vol. 31 , ( 12 ) 2099 - 2107 .

The Antiretroviral Therapy Cohort Collaboration COCC ( 2016 ) . Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada . AIDS vol. 30 , ( 3 ) 503 - 513 .

Rodger A, Lampe F, Burman W, Gruhlich A, Friedland G, El-Sadr W, Neaton J, Emery S et al. ( 2016 ) . Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Umaipalan A, Jayakumar A, Patel M, Wallis E, Baily G, Orkin C ( 2016 ) . Early virological response did not predict high levels of sustained virological response at 12 weeks (SVR12) in HIV/HCV-co-infected patients treated with directly acting agent (DAA)-containing therapy . HIV MEDICINE . vol. 17 , 45 - 45 .

Stohr W, Dunn D, Arenas-Pinto A, Paton N, Orkin C, Clarke A, Williams I, Johnson M et al. ( 2016 ) . Factors associated with virological rebound in patients receiving protease inhibitor monotherapy in the PIVOT trial . HIV MEDICINE . vol. 17 , 11 - 11 .

Barr E, Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G et al. ( 2016 ) . High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY . vol. 31 , 66 - 66 .

Dakshina S, Rieu R, Richards T, Cottrill C, Orkin C ( 2016 ) . Is there a role for a network-wide Kaposi sarcoma clinic in 2015? A review of transfers and clinical outcomes . HIV MEDICINE . vol. 17 , 66 - 66 .

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Yan M, Abram ME et al. ( 2016 ) . Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Marshall N, McNulty M, Smith C, Swaden L, Burns F, Orkin C ( 2016 ) . Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Umaipalan A, Dakshina S, Khan P, Bunker N, Orkin C ( 2016 ) . Routine HIV testing in critical care . HIV MEDICINE . vol. 17 , 56 - 56 .

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. ( 2016 ) . Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Orkin C, Clarke A, Gallant J, Daar E, Raffi F, Antonucci S, Mingjin Y, Chang A et al. ( 2016 ) . Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults . HIV MEDICINE . vol. 17 , 18 - 18 .

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer A, Lazzarin A, Soto-Malave R, Nelson M et al. ( 2016 ) . TURQUOISE-I Part 2: safety and efficacy of ombitasvir plus paritaprevir/r ±dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Rockstroh J, Orkin C, Viani R, Wyles D, Luetkemeyer A, Lazzarin A, Soto-Malave R, Nelson M et al. ( 2016 ) . TURQUOISE-I part 2: safety and efficacy of ombitasvir plus paritaprevir/r±dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,

Marwaha S, Dakshina S, Umaipalan A, Pasvol T, Baily G, Orkin C ( 2016 ) . The transfer times and outcomes of a tertiary in-patient HIV ward . HIV MEDICINE . vol. 17 , 69 - 69 .

Bath R, O'Connell R, Lascar M, Ferrand R, Strachan S, Matin N, Bassnet I, Orkin C ( 2015 ) . TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late diagnosis . AIDS Care vol. 28 , ( 5 ) 608 - 611 .

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte AD et al. ( 2015 ) . Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study . The Lancet HIV vol. 3 , ( 1 ) e23 - e32 .

Orkin C, Wallis E ( 2015 ) . Should HIV testing week be blood-borne-virus testing week? . The Lancet HIV vol. 2 , ( 12 ) e510 - e511 .

Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al. ( 2015 ) . The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy . AIDS vol. 29 , ( 17 ) 2269 - 2278 .

Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M et al. ( 2015 ) . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study . The Lancet Infectious Diseases vol. 16 , ( 1 ) 43 - 52 .

Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ et al. ( 2015 ) . Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study . PLOS ONE vol. 10 , ( 10 )

Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees? . Epidemiology and Infection vol. 143 , ( 13 ) 2837 - 2840 .

Orkin C, Umaipalan A ( 2015 ) . NtRTI sparing in patients at risk of bone disease . The Lancet HIV vol. 2 , ( 11 ) e452 - e453 .

Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F et al. ( 2015 ) . Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial . The Lancet HIV vol. 2 , ( 10 ) e417 - e426 .

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P et al. ( 2015 ) . Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals . Philosophical Transactions of the Royal Society B Biological Sciences vol. 370 , ( 1676 )

Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S, Ainsworth J, Allan S et al. ( 2015 ) . Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation . HIV Medicine vol. 17 , ( 5 ) 368 - 372 .

Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K et al. ( 2015 ) . The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK . PLOS ONE vol. 10 , ( 7 )

Pate KM, Pohlmeyer C, Walker‐Sperling V, Foote J, Najarro K, Cryer C, Salgado M, Gama L et al. ( 2015 ) . 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada . Journal of the International AIDS Society vol. 18 , ( 5Suppl 4 )

Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA et al. ( 2015 ) . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection . New England Journal of Medicine vol. 373 , ( 9 ) 795 - 807 .

Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM et al. ( 2015 ) . HIV resistance testing and detected drug resistance in Europe . AIDS vol. 29 , ( 11 ) 1379 - 1389 .

Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F et al. ( 2015 ) . The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels . AIDS vol. 29 , ( 11 ) 1355 - 1361 .

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS et al. ( 2015 ) . Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial . The Lancet HIV vol. 2 , ( 8 ) e319 - e327 .

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P et al. ( 2015 ) . Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study . The Lancet HIV vol. 2 , ( 8 ) e335 - e343 .

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M et al. ( 2015 ) . Liver-related death among HIV/hepatitis C virus-co-infected individuals . AIDS vol. 29 , ( 10 ) 1205 - 1215 .

Williams A, Wallis E, Orkin C ( 2015 ) . HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients? . International Journal of STD & AIDS vol. 27 , ( 7 ) 537 - 542 .

Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA, Database OBOTUHDR, Aitken C et al. ( 2015 ) . Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom . Clinical Infectious Diseases vol. 61 , ( 5 ) 829 - 836 .

Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M et al. ( 2015 ) . Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study . HIV Medicine vol. 16 , ( 9 ) 533 - 543 .

Boesecke C, Grint D, Soriano V, Lundgren JD, Monforte AD, Mitsura VM, Chentsova N, Hadziosmanovic V et al. ( 2015 ) . Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? . Liver International vol. 35 , ( 11 ) 2384 - 2391 .

Lederman M, Bautista‐Arredondo S, Bertozzi S, Sosa‐Rubi S, Gulick R, del Rio C, Beyrer C, Román E et al. ( 2015 ) . HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico . Journal of the International AIDS Society vol. 18 , ( 3Suppl 2 )

Santana J, Rockstroh J, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B et al. ( 2015 ) . O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials . Journal of the International AIDS Society vol. 18 , ( 3 (Suppl 2) )

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M et al. ( 2015 ) . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials . The Lancet vol. 385 , ( 9987 ) 2606 - 2615 .

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag M et al. ( 2015 ) . P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV . Journal of Hepatology vol. 62 ,

Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY ( 2015 ) . P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees? . Journal of Hepatology . vol. 62 ,

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D et al. ( 2015 ) . Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study . PLOS Medicine vol. 12 , ( 3 )

Flanagan S, Umaipalan A, Baily G, Orkin C ( 2015 ) . Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment . Journal of AIDS and HIV Research vol. 7 , ( 3 ) 33 - 35 .

Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al. ( 2015 ) . Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy . AIDS vol. 29 , ( 7 ) 801 - 809 .

Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina J-M, Wood R, Neaton JD ( 2015 ) . Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial . HIV Medicine vol. 16 , ( S1 ) 1 - 9 .

ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? . Epidemiology and Infection vol. 143 , ( 13 ) 2837 - 2840 .

Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R et al. ( 2015 ) . A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals . PLOS ONE vol. 10 , ( 2 )

Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, Massetto B, Gaggar A et al. ( 2015 ) . Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study . The Lancet vol. 385 , ( 9973 ) 1098 - 1106 .

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J et al. ( 2015 ) . Structured Observations Reveal Slow HIV-1 CTL Escape . PLOS Genetics vol. 11 , ( 2 )

Bath R, Ahmad K, Orkin C ( 2015 ) . Routine HIV testing within the emergency department of a major trauma centre: a pilot study . HIV Medicine vol. 16 , ( 5 ) 326 - 328 .

Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL ( 2015 ) . Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes . The Journal of Infectious Diseases . vol. 212 , 367 - 377 .

Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R et al. ( 2015 ) . Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries . Clinical Infectious Diseases vol. 60 , ( 8 ) 1262 - 1268 .

Deayton J, O'Sullivan E, McKnight A, Groves K, Bibby D, Clark D, Orkin C, Reeves I et al. ( 2015 ) . Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy . HIV MEDICINE vol. 16 , 20 - 20 .

Raman L, Duschl J, Wallis E, Orkin C ( 2015 ) . Effectiveness of opt-out HIV testing on a medical assessment unit in a high-prevalence area . HIV MEDICINE . vol. 16 , 49 - 49 .

Rockstroh JK, Nelson M, Katlama C, Lalezari JP, Mallolas J, Bloch M, Matthews G, Saag M et al. ( 2015 ) . High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study . HEPATOLOGY . vol. 62 , 317A - 317A .

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag MS et al. ( 2015 ) . High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 18 ,

Wallis E, Umaipalan A, Flanagan S, Montoto S, Orkin C ( 2015 ) . Post chemotherapy liver dysfunction and reactivation of Hepatitis B (HBV) and C (HCV) in an HIV-infected cohort . HIV MEDICINE vol. 16 , 41 - 41 .

Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM et al. ( 2014 ) . Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease . AIDS vol. 28 , ( 17 ) 2565 - 2571 .

Berkowitz EM, Moyle G, Stellbrink H-J, Schürmann D, Kegg S, Stoll M, Idrissi ME, Oostvogels L et al. ( 2014 ) . Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study . The Journal of Infectious Diseases vol. 211 , ( 8 ) 1279 - 1287 .

Mahy M, Nzima M, Ogungbemi MK, Ogbang DA, Morka MC, Stover J ( 2014 ) . Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries . AIDS vol. 28 , ( 16 ) 2461 - 2473 .

Wallis E, Thornhill J, Saunders J, Orkin C ( 2014 ) . Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia? . Sexually Transmitted Infections vol. 91 , ( 3 )

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D et al. ( 2014 ) . HIV-1 DNA predicts disease progression and post-treatment virological control . eLife vol. 3 ,

Flanagan S, Crawford-Jones A, Orkin C ( 2014 ) . Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection . Expert Review of Clinical Pharmacology vol. 7 , ( 6 ) 691 - 704 .

Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A et al. ( 2014 ) . Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study . Clinical Infectious Diseases vol. 59 , ( 11 ) 1579 - 1587 .

Hué S, Brown AE, Ragonnet-Cronin M, Lycett SJ, Dunn DT, Fearnhill E, Dolling DI, Pozniak A et al. ( 2014 ) . Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions . AIDS vol. 28 , ( 13 ) 1967 - 1975 .

Thornhill J, Sivaramakrishnan A, Orkin C ( 2014 ) . Pneumococcal vaccination in people living with HIV . Vaccine vol. 33 , ( 28 ) 3159 - 3160 .

Arenas-Pinto A, Winston A, Stöhr W, Day J, Wiggins R, Quah SP, Ainsworth J, Fleck S et al. ( 2014 ) . Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment . PLOS ONE vol. 9 , ( 7 )

Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H et al. ( 2014 ) . Intercontinental Dispersal of HIV-1 Subtype B Associated with Transmission among Men Who Have Sex with Men in Japan . Journal of Virology vol. 88 , ( 17 ) 9864 - 9876 .

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD, Committee TIESGASS ( 2014 ) . Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation . Journal of the American Heart Association vol. 3 , ( 3 )

Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F et al. ( 2014 ) . Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy . AIDS vol. 28 , ( 9 ) 1333 - 1339 .

Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D, Brown AJL et al. ( 2014 ) . The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection . PLOS Pathogens vol. 10 , ( 5 )

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M et al. ( 2014 ) . Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy . AIDS vol. 28 , ( 8 ) 1193 - 1202 .

Thornhill J, Mandersloot G, Bath R, Orkin C ( 2014 ) . Opt-out HIV testing in adult critical care units . The Lancet vol. 383 , ( 9927 )

O’Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M et al. ( 2014 ) . Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression . AIDS vol. 28 , ( 6 ) 919 - 924 .

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M et al. ( 2014 ) . Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression . AIDS vol. 28 , ( 6 ) 869 - 874 .

Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW et al. ( 2014 ) . The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study . PLOS ONE vol. 9 , ( 3 )

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S et al. ( 2014 ) . Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis . AIDS Patient Care and STDs vol. 28 , ( 4 ) 168 - 175 .

Borges ÁH, O’Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G et al. ( 2014 ) . Factors Associated with D-Dimer Levels in HIV-Infected Individuals . PLOS ONE vol. 9 , ( 3 )

Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Papanastasopoulos P et al. ( 2014 ) . HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era . AIDS vol. 28 , ( 5 ) 689 - 697 .

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J et al. ( 2014 ) . HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression . AIDS vol. 28 , ( 5 ) 699 - 708 .

Huntington S, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T, Tookey P et al. ( 2014 ) . Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women . BMC Infectious Diseases vol. 14 , ( 1 )

Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J et al. ( 2014 ) . Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure . The Journal of Infectious Diseases vol. 210 , ( 3 ) 363 - 373 .

( 2014 ) . The increasing genetic diversity of HIV-1 in the UK, 2002–2010 . AIDS vol. 28 , ( 5 ) 773 - 780 .

Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O et al. ( 2014 ) . Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis . AIDS vol. 28 , ( 4 ) 577 - 587 .

Group W, Bower M, Palfreeman A, Alfa‐Wali M, Bunker C, Burns F, Churchill D, Collins S et al. ( 2014 ) . British HIV Association guidelines for HIV‐associated malignancies 2014 . HIV Medicine vol. 15 , ( S2 ) 1 - 92 .

Shepherd L, Souberbielle J-C, Bastard J-P, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A et al. ( 2014 ) . Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons . The Journal of Infectious Diseases vol. 210 , ( 2 ) 234 - 243 .

Foster GM, Ambrose JC, Hué S, Delpech VC, Fearnhill E, Abecasis AB, Leigh Brown AJ, Geretti AM ( 2014 ) . Novel HIV-1 Recombinants Spreading across Multiple Risk Groups in the United Kingdom: The Identification and Phylogeography of Circulating Recombinant Form (CRF) 50_A1D . PLOS ONE vol. 9 , ( 1 )

Bath R, O'Connell R, Lascar M, Ferrand R, Matin N, Basnett I, Apea V, Phiri E et al. ( 2014 ) . #TestMeEast@EuroHIVTestingWeek: a celebrity-endorsed, newsworthy NHS campaign across six hospitals to test 2500 patients (500/day) based in outpatients (OPD) and emergency departments (ED): the results . HIV MEDICINE . vol. 15 , 95 - 95 .

Wikeley S, Bradbury R, Bath R, O'Connell R, Matin N, Saunders J, Lascar M, Phiri E et al. ( 2014 ) . 'Legion' of medical students participates in largest hospital-based HIV testing week initiative - breaking down testing barriers in the doctors of tomorrow . HIV MEDICINE . vol. 15 , 91 - 91 .

Thornhill J, Mandersloot G, Bath R, Orkin C ( 2014 ) . Erratum: Opt-out HIV testing in adult critical care units (Lancet (2014) 383 (1460)) . The Lancet vol. 383 , ( 9930 )

Krupiczojc M, Goldsmith P, Cerio R, Orkin C, Williams E, Harwood C ( 2014 ) . Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease . BRITISH JOURNAL OF DERMATOLOGY . vol. 171 , 101 - 102 .

Thornhill J, Mandersloot G, Bath R, Orkin C ( 2014 ) . Opt-out HIV testing in adult critical care units (vol 383, pg 1460, 2014) . LANCET vol. 383 , ( 9930 ) 1720 - 1720 .

Wilkins E, Moyle G, Orkin C, Fisher M, Johnson M, Arribas J, Van Lunzen J, Garner W et al. ( 2014 ) . STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA ≤ 100,000 copies/mL through week 96 . HIV MEDICINE . vol. 15 , 115 - 116 .

Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES et al. ( 2014 ) . Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials . HEPATOLOGY . vol. 60 , 295A - 296A .

Keikawus A, Murray D, Junhai G, Jean-Michel L, Chloe O, Ann-Marie Q, Douglas WP ( 2014 ) . TRANxITION 144 Week Results: Switching Virologically Stable HIV Patients from Immediate-release Nevirapine (NVP IR) to Extended-Release NVP (XR) . Journal of AIDS & Clinical Research vol. 05 , ( 04 )

Orkin C, Wohl DA, Williams A, Deckx H ( 2014 ) . Vitamin D deficiency in HIV: a shadow on long-term management? . Aids Reviews vol. 16 , ( 2 ) 59 - 74 .

Orkin C, Clumeck N, Girard P-M, Henry K, Gathe J, Rockstroh J, DeJesus E, Yau S et al. ( 2014 ) . Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients . HIV MEDICINE . vol. 15 , 114 - 114 .

Group W, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K et al. ( 2013 ) . British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) . HIV Medicine vol. 15 , ( S1 ) 1 - 6 .

Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y et al. ( 2013 ) . Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz . Journal of Antimicrobial Chemotherapy vol. 69 , ( 4 ) 1090 - 1097 .

Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C et al. ( 2013 ) . The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations . HIV Medicine vol. 15 , ( 5 ) 311 - 316 .

Group W, Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G et al. ( 2013 ) . British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013 . HIV Medicine vol. 14 , ( S4 ) 1 - 71 .

( 2013 ) . HLA B*5701 status, disease progression, and response to antiretroviral therapy . AIDS vol. 27 , ( 16 ) 2587 - 2592 .

Boffito M, Fox J, Bowman C, Fisher M, Orkin C, Wilkins E, Jackson A, Pleguezuelos O et al. ( 2013 ) . Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial . Vaccine vol. 31 , ( 48 ) 5680 - 5686 .

Moyle GJ, Stellbrink H-J, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H et al. ( 2013 ) . 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study . Antiviral Therapy vol. 18 , ( 7 ) 905 - 913 .

Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F et al. ( 2013 ) . Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure . PLOS ONE vol. 8 , ( 9 )

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C et al. ( 2013 ) . The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults . AIDS vol. 27 , ( 14 ) 2245 - 2253 .

Molina J, Clumeck N, Orkin C, Rimsky, Vanveggel S, Stevens M, Groups EATS ( 2013 ) . Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials . HIV Medicine vol. 15 , ( 1 ) 57 - 62 .

Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT, Resistance FTUCGOHD et al. ( 2013 ) . Persistence of HIV-1 Transmitted Drug Resistance Mutations . The Journal of Infectious Diseases vol. 208 , ( 9 ) 1459 - 1463 .

Grint D, Peters L, Schwarze‐Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V et al. ( 2013 ) . Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA . HIV Medicine vol. 14 , ( 10 ) 614 - 623 .

Wallis E, Saunders J, Orkin C ( 2013 ) . P2.042 An Audit of HIV Testing Rates in Patients Admitted with Pneumonia Pre- and Post- Implementation of Opt-Out HIV Testing For Acute Medical Admissions . Sexually Transmitted Infections vol. 89 , ( Suppl 1 )

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA et al. ( 2013 ) . Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study . Journal of Antimicrobial Chemotherapy vol. 68 , ( 10 ) 2339 - 2343 .

Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A et al. ( 2013 ) . Stability of hepatitis C virus (HCV) RNA levels among interferon‐naïve HIV/HCV‐coinfected individuals treated with combination antiretroviral therapy . HIV Medicine vol. 14 , ( 6 ) 370 - 378 .

Cohen CJ, Molina J-M, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink H-J et al. ( 2013 ) . Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials . AIDS vol. 27 , ( 6 ) 939 - 950 .

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B et al. ( 2013 ) . Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring . Journal of Antimicrobial Chemotherapy vol. 68 , ( 6 ) 1354 - 1359 .

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C et al. ( 2013 ) . Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study . PLOS ONE vol. 8 , ( 2 )

Koning FA, Castro H, Dunn D, Tilston P, Cane PA, Mbisa JL, Resistance OBOTUCGOHD ( 2013 ) . Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors . Journal of Antimicrobial Chemotherapy vol. 68 , ( 6 ) 1220 - 1236 .

Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al. ( 2013 ) . Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo) . Antiviral Therapy vol. 19 , ( 2 ) 191 - 200 .

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D et al. ( 2013 ) . Second-Line Protease Inhibitor-Based Antiretroviral Therapy after Non-Nucleoside Reverse Transcriptase Inhibitor Failure: The Effect of a Nucleoside Backbone . Antiviral Therapy vol. 18 , ( 2 ) 213 - 219 .

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R ( 2013 ) . Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection . AIDS vol. 27 , ( 3 ) 313 - 323 .

Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, Orkin C, Fisher M et al. ( 2013 ) . NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials . AIDS Research and Therapy vol. 10 , ( 1 )

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN et al. ( 2013 ) . Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters . Retrovirology vol. 10 , ( 1 )

Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M et al. ( 2013 ) . Short-Course Antiretroviral Therapy in Primary HIV Infection . New England Journal of Medicine vol. 368 , ( 3 ) 207 - 217 .

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A et al. ( 2013 ) . Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe . The Journal of Infectious Diseases vol. 207 , ( 8 ) 1216 - 1220 .

Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al. ( 2013 ) . Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study . The Lancet vol. 381 , ( 9868 ) 735 - 743 .

Huntington SE, Thorne C, Bansi LK, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al. ( 2013 ) . Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care . AIDS vol. 27 , ( 1 ) 95 - 103 .

Thornhill J, Wallis E, Cho S, Khan P, Sivaramakrishnan A, Amin A, Orkin C ( 2013 ) . Cross-sectional analysis of invasive pneumococcal disease in a London HIV-positive cohort . HIV MEDICINE . vol. 14 , 67 - 67 .

Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al. ( 2013 ) . HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA . HAEMATOLOGICA . vol. 98 , 129 - 129 .

Hartley A, Annesley C, Davies K, Orkin C, Williams A ( 2013 ) . In an ageing HIV positive cohort with mixed gender and sexuality, is bone mineral density impaired? . HIV MEDICINE . vol. 14 , 23 - 23 .

Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N et al. ( 2013 ) . Neurocognitive function in HIV infected patients on antiretroviral therapy . PLoS One vol. 8 , ( 4 )

Zolopa A, Rockstroh J, Orkin C, Stellbrink H-J, Walmsley S, Cooper D, Zhong L, Fordyce M et al. ( 2013 ) . Ninety-six-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF - subgroup analyses by baseline HIV-1 RNA and CD4 cells . PHARMACOTHERAPY . vol. 33 , E210 - E211 .

Tariq S, Bath R, Tillett S, Nori A, Saunders J, Mandersloot G, Orkin C ( 2013 ) . Opt-out HIV testing within intensive care in a large urban hospital: an innovative testing initiative . HIV MEDICINE . vol. 14 , 46 - 46 .

Williams E, Bath R, Vaidh N, Tillett S, Mandersloot G, Poole N, Saunders J, Tariq S et al. ( 2013 ) . Project 'Test the Hospital' . HIV MEDICINE . vol. 14 , 47 - 47 .

Cresswell F, Gothard A, Cevik M, Haidari G, Alexander H, Katsarolis I, McGinty T, Wolujewic A et al. ( 2013 ) . Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera®) in hepatitis C-HIV coinfection . ANTIVIRAL THERAPY . vol. 18 , A61 - A61 .

Orkin C, Rockstroh J, DeJesus E, Henry K, Molina J, Gathe J, Wei X, Fordyce M et al. ( 2013 ) . Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients . HIV MEDICINE . vol. 14 , 56 - 56 .

Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ et al. ( 2012 ) . Disease Progression in HIV-1–Infected Viremic Controllers . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 61 , ( 4 ) 407 - 416 .

Cohen M, Perno C, El‐Sadr W, Molina J, Saag M, Lundgren J, Mussini C, Reiss P et al. ( 2012 ) . Eleventh International Congress on Drug Therapy in HIV Infection . Journal of the International AIDS Society vol. 15 ,

Molina J, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M ( 2012 ) . Rilpivirine efficacy, virology and safety in ARV treatment‐naïve patients with viral load≤100,000 HIV‐1 RNA c/mL: ECHO and THRIVE 96‐week results . Journal of the International AIDS Society . vol. 15 , 1 - 2 .

Arastéh K, Drulak M, Guo J, Livrozet J, Orkin C, Quinson A, Ward D ( 2012 ) . TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR) . Journal of the International AIDS Society . vol. 15 , 1 - 1 .

Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M et al. ( 2012 ) . Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study . PLOS ONE vol. 7 , ( 11 )

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M et al. ( 2012 ) . Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial . HIV Medicine vol. 14 , ( 1 ) 49 - 59 .

Kyrychenko T, Dubynska G, Koval T, Kaidashev I, Korshenko V, Rono K, Kibuuka H, Maganga L et al. ( 2012 ) . Track B Clinical Science . Journal of the International AIDS Society vol. 15 , ( Suppl 3 ) 18439 - 18401 .

Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J ( 2012 ) . Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study . PLOS ONE vol. 7 , ( 10 )

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2012 ) . HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era . Journal of Clinical Oncology vol. 30 , ( 33 ) 4111 - 4116 .

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF et al. ( 2012 ) . Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection . PLOS ONE vol. 7 , ( 8 )

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R et al. ( 2012 ) . The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study . AIDS vol. 26 , ( 13 ) 1691 - 1705 .

Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D et al. ( 2012 ) . Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study . The BMJ vol. 345 , ( aug21 2 )

Orkin C, Nelson M, Katlama C, Morlat P, Furrer H, van Delft Y, Janssen M, Hill A et al. ( 2012 ) . Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz . Health Outcomes Research in Medicine vol. 3 , ( 3 ) e113 - e119 .

Huntington SE, Bansi LK, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al. ( 2012 ) . Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women . BMC Medical Research Methodology vol. 12 , ( 1 )

Group W, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K et al. ( 2012 ) . British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 . HIV Medicine vol. 13 , ( S2 ) 1 - 6 .

Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ et al. ( 2012 ) . Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy: A Randomized Controlled Trial . JAMA vol. 308 , ( 4 ) 353 - 361 .

Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C et al. ( 2012 ) . Biomarkers to Monitor Safety in People on ART and Risk of Mortality . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 60 , ( 1 ) 51 - 58 .

Nelson M, Amaya G, Clumeck N, da Cunha CA, Jayaweera D, Junod P, Li T, Tebas P et al. ( 2012 ) . Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials . Journal of Antimicrobial Chemotherapy vol. 67 , ( 8 ) 2020 - 2028 .

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S et al. ( 2012 ) . Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection . AIDS vol. 26 , ( 7 ) 887 - 890 .

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA, Group CHCCS ( 2012 ) . Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients . American Journal of Kidney Diseases vol. 60 , ( 4 ) 539 - 547 .

( 2012 ) . Uptake and Outcome of Combination Antiretroviral Therapy in Men Who Have Sex with Men According to Ethnic Group . JAIDS Journal of Acquired Immune Deficiency Syndromes . vol. 59 , 523 - 529 .

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I et al. ( 2012 ) . Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries . Clinical Infectious Diseases vol. 54 , ( 9 ) 1364 - 1372 .

Castro H, Pillay D, Sabin C, Dunn DT, the UK Collaborative Group on HIV Drug Resistance ( 2012 ) . Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance . BMC Medical Research Methodology vol. 12 , ( 1 )

Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D et al. ( 2012 ) . Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy? . The Journal of Infectious Diseases vol. 205 , ( 4 ) 540 - 547 .

Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF ( 2012 ) . A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 59 , ( 2 ) 126 - 133 .

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D et al. ( 2012 ) . Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor . Journal of Antimicrobial Chemotherapy vol. 67 , ( 4 ) 995 - 1000 .

DeJesus E, Orkin C, Rockstroh J, Molina J-M, White K, Wei X, Plummer A, Kearney B et al. ( 2012 ) . Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks . HIV MEDICINE . vol. 13 , 9 - 9 .

Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al. ( 2012 ) . HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . HIV MEDICINE vol. 13 , 5 - 5 .

Williams A, Uthayakumar A, De Souza C, Murthen L, Hand J, Apea V, Orkin C ( 2012 ) . HIV research trials versus standard clinics for antiretroviral (ARV) naive patients: the outcomes differ but do the patients? . HIV MEDICINE . vol. 13 , 76 - 76 .

Orkin C, Arribas J, Hodder S, Stellbrink HJ, Vanveggel S, Deckx H, Stevens M ( 2012 ) . Incidence of rash in the 96-week analysis of the pooled Phase III randomised double-blind ECHO and THRIVE trials . HIV MEDICINE . vol. 13 , 50 - 50 .

Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al. ( 2012 ) . Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 15 , 55 - 55 .

Orkin C, Cohen C, Molina J-M, Cassetti I, Chetchotisakd P, Lazzarin A, Rhame F, Stellbrink HJ et al. ( 2012 ) . Pooled Week 96 efficacy and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV;TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults . HIV MEDICINE . vol. 13 , 68 - 69 .

Williams A, Goh B, Orkin C ( 2012 ) . SpR Trek: the next generation . HIV MEDICINE . vol. 13 , 17 - 17 .

Dhairyawan R, Lowe S, Ncube B, Jones A, Strachen S, Apea V, Orkin C ( 2012 ) . The first 9 months: the lost to follow up (LTFU) clinic is born. A sustained approach to re-engaging patients . HIV MEDICINE . vol. 13 , 77 - 77 .

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y et al. ( 2011 ) . Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial . Journal of Antimicrobial Chemotherapy vol. 67 , ( 3 ) 685 - 690 .

Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti A, Kelleher P et al. ( 2011 ) . British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 . HIV Medicine vol. 13 , ( 1 ) 1 - 44 .

Arasteh K, Ward D, Plettenberg A, Livrozet J, Orkin C, Cordes C, Guo J, Wang E et al. ( 2011 ) . Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION) . HIV Medicine vol. 13 , ( 4 ) 236 - 244 .

Dhairyawan R, Longwill S, Orkin C, Montoto S ( 2011 ) . An innovative joint approach to HIV and lymphoma care . Sexually Transmitted Infections vol. 88 , ( 1 )

Dua J, Nori A, Elliot E, Goh B, Orkin C ( 2011 ) . Blinded by love: Ocular syphilis as the initial manifestation of HIV Category: Clinical lesson . Journal of Infection vol. 63 , ( 6 )

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA ( 2011 ) . Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients . Nephrology Dialysis Transplantation vol. 27 , ( 6 ) 2291 - 2297 .

Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A et al. ( 2011 ) . Non‐uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK . HIV Medicine vol. 13 , ( 1 ) 73 - 78 .

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era, . Blood vol. 118 , ( 21 )

May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A et al. ( 2011 ) . Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study . The BMJ vol. 343 , ( oct11 2 )

Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G ( 2011 ) . Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration . Journal of Clinical Virology vol. 52 , ( 4 ) 367 - 369 .

Huntington SE, Bansi LK, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al. ( 2011 ) . Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception . AIDS vol. 25 , ( 13 ) 1647 - 1655 .

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T et al. ( 2011 ) . Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study . Antiviral Therapy vol. 16 , ( 6 ) 805 - 814 .

English S, Katzourakis A, Bonsall D, Flanagan P, Duda A, Fidler S, Weber J, McClure M et al. ( 2011 ) . Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants . Retrovirology vol. 8 , ( 1 )

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al. ( 2011 ) . Authors' response to Drs Scourfield, Jackson and Nelson . HIV Medicine vol. 12 , ( 7 ) 450 - 451 .

Prosperi MCF, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A et al. ( 2011 ) . Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study . Journal of Antimicrobial Chemotherapy vol. 66 , ( 8 ) 1886 - 1896 .

Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J et al. ( 2011 ) . Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study . HIV Medicine vol. 12 , ( 10 ) 583 - 593 .

Donegan KL, Walker AS, Dunn D, Judd A, Pillay D, Menson E, Lyall H, Tudor-Williams G et al. ( 2011 ) . The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk . Antiviral Therapy vol. 17 , ( 4 ) 599 - 603 .

Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, Bansi L, Justice A, Goulet J et al. ( 2011 ) . When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study . Annals of Internal Medicine vol. 154 , ( 8 ) 509 - 515 .

Bird SR, Noronha M, Kurowski W, Orkin C, Sinnott H ( 2011 ) . Integrated Care Facilitation Model Reduces Use of Hospital Resources by Patients with Pediatric Asthma . Journal for Healthcare Quality vol. 34 , ( 3 ) 25 - 33 .

Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, Horne R, group FTS ( 2011 ) . Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz . AIDS Care vol. 23 , ( 6 ) 705 - 713 .

Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK et al. ( 2011 ) . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial . PLOS ONE vol. 6 , ( 3 )

Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ et al. ( 2011 ) . N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients . AIDS vol. 25 , ( 5 ) 651 - 657 .

Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al. ( 2011 ) . Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease(CME) . Neurology vol. 76 , ( 8 ) 693 - 700 .

Lazzarin A, Orkin C, De Jesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E et al. ( 2011 ) . ARTEMIS: 192-WEEK EFFICACY AND SAFETY OF ONCE DAILY DARUNAVIR/RITONAVIR (DRV/R) VERSUS LOPINAVIR/R (LPV/R) IN TREATMENT-NAIVE HIV-1-INFECTED ADULTS . INFECTION . vol. 39 , S26 - S27 .

Dhairyawan R, Longwill S, Orkin C, Montoto S ( 2011 ) . An innovative joint approach to HIV and lymphoma care . HIV MEDICINE vol. 12 , 38 - 38 .

Castagna A, Lazzarin A, Carosi G, Andreoni M, Orkin C, Streinu-Cercel A, Erscoiu S, Nelson M et al. ( 2011 ) . CHANGES IN PATIENT-REPORTED OUTCOMES DURING THE SENSE TRIAL: FIRST-LINE TREATMENT WITH 2 NRTIS PLUS ETRAVIRINE OR EFAVIRENZ . INFECTION . vol. 39 , S64 - S64 .

Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al. ( 2011 ) . Change in vitamin D levels smaller, and risk of development of severe vitamin D deficiency lower, among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the Phase III ECHO trial . HIV MEDICINE . vol. 12 , 1 - 1 .

Dua J, Nori A, Cottrill C, Orkin C ( 2011 ) . Cutaneous Kaposi's sarcoma: a case of mistaken identity . HIV MEDICINE . vol. 12 , 40 - 40 .

Hartley A, Garrett N, Orkin C, Sarner L, Ault N ( 2011 ) . Does better tolerated antiretroviral therapy (ART) allow us to modernize post-exposure prophylaxis (PEP) . HIV MEDICINE . vol. 12 , 15 - 16 .

Draeger E, Smith K, Hogan S, Orkin C ( 2011 ) . Evaluation of a new clinic model: increasing enrolment into clinical trials without increasing staffing or costs . HIV MEDICINE . vol. 12 , 19 - 20 .

Longwill S, Nori A, Orkin C, O'Connell B, Creighton S, Dorward J, Reeves I ( 2011 ) . First contact: exploring relationships between HIV clinics, primary care, geography and HIV diagnoses in North East London . HIV MEDICINE . vol. 12 , 64 - 64 .

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . BLOOD . vol. 118 , 1557 - 1557 .

Nori A, Jethwa N, Chung E, Orkin C ( 2011 ) . HIV in the older patient: an overlooked population? . HIV MEDICINE . vol. 12 , 67 - 67 .

Byrne L, Whitburn T, Vearncombe S, Orkin C, Noble H ( 2011 ) . HIV specialists must lead the way to make HIV testing truly routine . HIV MEDICINE . vol. 12 , 64 - 65 .

Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G ( 2011 ) . Successful treatment of acute hepatitis C virus in a cohort of HIV-positive patients . HIV MEDICINE . vol. 12 , 43 - 43 .

Moyle G, Orkin C, Fisher M, Taylor S, Ross J, Wang H, Simcock C ( 2011 ) . Switching to a simplified single-tablet regimen (STR) of Atripla (ATR) from a two- or three-pill combination of the individual components (efavirenz [EFV], emtricitabine [FTC] and tenofovir DF [TDF]) maintains virological suppression: primary endpoint results of a 48-week, open-label study . HIV MEDICINE vol. 12 , 79 - 79 .

Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al. ( 2010 ) . HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era . European Journal of Neurology vol. 18 , ( 3 ) 527 - 534 .

Fryer HR, Frater J, Duda A, Roberts MG, Phillips RE, McLean AR ( 2010 ) . Modelling the Evolution and Spread of HIV Immune Escape Mutants . PLOS Pathogens vol. 6 , ( 11 )

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E, Spinosa‐Guzman S ( 2010 ) . ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adults . Journal of the International AIDS Society vol. 13 , ( Suppl 4 ) p3 - p3 .

Moyle G, Orkin C, Fisher M, Anderson J, Dhar J, Wang M, Ewan J ( 2010 ) . Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24‐week, randomized study . Journal of the International AIDS Society vol. 13 , ( Suppl 4 ) p80 - p80 .

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al. ( 2010 ) . Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters . HIV Medicine vol. 12 , ( 5 ) 289 - 298 .

Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G et al. ( 2010 ) . Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study . Clinical Infectious Diseases vol. 51 , ( 8 ) 963 - 972 .

Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D et al. ( 2010 ) . HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom . Antiviral Therapy vol. 15 , ( 7 ) 985 - 991 .

Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S ( 2010 ) . Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK . AIDS vol. 24 , ( 15 ) 2397 - 2401 .

Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A et al. ( 2010 ) . Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection . Journal of General Virology vol. 91 , ( 11 ) 2794 - 2803 .

Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D ( 2010 ) . The effect of transmitted HIV-1 drug resistance on pre-therapy viral load . AIDS vol. 24 , ( 12 ) 1917 - 1922 .

Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A et al. ( 2010 ) . Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study . The Lancet vol. 376 , ( 9738 ) 340 - 345 .

Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P et al. ( 2010 ) . Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations* . HIV Medicine vol. 11 , ( 7 ) 432 - 438 .

Orkin C, Wang J, Bergin C, Molina J-M, Lazzarin A, Cavassini M, Esser S, Sirvent J-LG et al. ( 2010 ) . An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe . Pharmacogenetics and Genomics vol. 20 , ( 5 ) 307 - 314 .

Group CGOHDRAUCS ( 2010 ) . Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy . Clinical Infectious Diseases vol. 50 , ( 9 ) 1275 - 1285 .

Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M et al. ( 2010 ) . Data linkage reduces loss to follow-up in an observational HIV cohort study . Journal of Clinical Epidemiology vol. 63 , ( 10 ) 1101 - 1109 .

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M et al. ( 2010 ) . Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma . AIDS vol. 24 , ( 6 ) 851 - 856 .

Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T et al. ( 2010 ) . Late diagnosis in the HAART era: proposed common definitions and associations with mortality . AIDS vol. 24 , ( 5 ) 723 - 727 .

Tavel JA, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D et al. ( 2010 ) . Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study . PLOS ONE vol. 5 , ( 2 )

de Oliveira T, Pillay D, Gifford RJ ( 2010 ) . The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom . PLOS ONE vol. 5 , ( 2 )

Orkin C, Sadiq, Rice L, Jackson F, team OBOTUE ( 2010 ) . Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B*5701 in HIV‐1‐infected UK subjects . HIV Medicine vol. 11 , ( 3 ) 187 - 192 .

Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D et al. ( 2010 ) . Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals . PLOS ONE vol. 5 , ( 1 )

Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R et al. ( 2010 ) . Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials . The Lancet vol. 375 , ( 9712 ) 396 - 407 .

Gilson R, Man S, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K et al. ( 2010 ) . Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study* . HIV Medicine vol. 11 , ( 2 ) 152 - 160 .

Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A et al. ( 2010 ) . The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals . AIDS vol. 24 , ( 1 ) 123 - 137 .

Orkin C, Streinu-Cercel A, Erscoiu S, Nelson M, Hill A, van Delft Y, Marks S ( 2010 ) . Changes in patient-reported outcomes during the SENSE Trial: first-line treatment with 2 NRTIs plus etravirine or efavirenz . ANTIVIRAL THERAPY . vol. 15 , A69 - A69 .

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas J, Domingo P, Granier C, Pearce H et al. ( 2010 ) . Comparison of bone and renal toxicities in the ASSERT study: final 96 week results from a prospective randomized safety trial . ANTIVIRAL THERAPY . vol. 15 , A19 - A19 .

Deayton J, Bibby D, Orkin C, O'Sullivan E, McKnight A, Clark D ( 2010 ) . Inter-clade dual HIV-1 infection in the UK - an emerging phenomenon .

Bower M, Montoto S, Cwynarski K, Lumsden AS, Rajab R, Okosun J, Orkin C, Nelson M et al. ( 2010 ) . Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival . HIV MEDICINE vol. 11 , 13 - 13 .

Waters L, Asboe D, Pozniak A, Bansi L, Orkin C, Smit E, Fearnhill E, Phillips A ( 2010 ) . Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART . HIV MEDICINE . vol. 11 , 3 - 4 .

Orkin C, Moyle G, Fisher M, Wang H, Ewan J ( 2010 ) . Switching from Kivexa [KVX] ABC/3TC+efavirenz [EFV] to Atripla [ATR] (EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects: preliminary results of a 24-week randomized study . HIV MEDICINE vol. 11 , 4 - 4 .

Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J et al. ( 2009 ) . Clinical epidemiology of HIV-associated end-stage renal failure in the UK . AIDS vol. 23 , ( 18 ) 2517 - 2521 .

Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B et al. ( 2009 ) . Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? . AIDS vol. 23 , ( 18 ) 2507 - 2515 .

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina J-M, Schechter M, Peeters M et al. ( 2009 ) . Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials . AIDS vol. 23 , ( 17 ) 2289 - 2300 .

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al. ( 2009 ) . Factors influencing lopinavir and atazanavir plasma concentration . Journal of Antimicrobial Chemotherapy vol. 65 , ( 1 ) 129 - 137 .

Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K et al. ( 2009 ) . Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 52 , ( 3 ) 391 - 396 .

Dreja H, O'Sullivan E, Pade C, Aubin K, Isaksen A, D'Souza C, Hand J, Orkin C et al. ( 2009 ) . P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients . Retrovirology vol. 6 , ( Suppl 3 )

Groves K, Bibby D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg A, McKnight Á ( 2009 ) . P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts . Retrovirology vol. 6 , ( Suppl 3 )

Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A et al. ( 2009 ) . The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes . Journal of Viral Hepatitis vol. 17 , ( 8 ) 569 - 577 .

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB et al. ( 2009 ) . Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection . The Journal of Infectious Diseases . vol. 200 , 973 - 983 .

Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T et al. ( 2009 ) . Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir . The Journal of Infectious Diseases vol. 200 , ( 5 ) 710 - 714 .

Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS et al. ( 2009 ) . Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy . AIDS vol. 23 , ( 13 ) 1689 - 1699 .

Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H et al. ( 2009 ) . A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals . JAIDS Journal of Acquired Immune Deficiency Syndromes . vol. 51 , 562 - 568 .

Khachi H, O'Connell R, Ladenheim D, Orkin C ( 2009 ) . Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection . Journal of Antimicrobial Chemotherapy vol. 64 , ( 4 ) 871 - 873 .

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D et al. ( 2009 ) . Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy . Clinical Infectious Diseases vol. 48 , ( 9 ) 1296 - 1305 .

Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L et al. ( 2009 ) . CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK . Haematologica vol. 94 , ( 6 ) 875 - 880 .

Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D ( 2009 ) . Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naïve Individuals . Journal of Virology vol. 83 , ( 6 ) 2645 - 2654 .

Yeni P, LaMarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill F, Teofilo E et al. ( 2009 ) . Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)* . HIV Medicine vol. 10 , ( 2 ) 116 - 124 .

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M et al. ( 2009 ) . Interruption of antiretroviral therapy is associated with increased plasma cystatin C . AIDS vol. 23 , ( 1 ) 71 - 82 .

Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson M, Bower M, Cwynarski K ( 2009 ) . Excellent immunological recovery following the intensive chemotherapy CODOX-M/IVAC, an effective therapy for HIV-associated Burkitt's lymphoma . HIV MEDICINE vol. 10 , 5 - 5 .

Sabin C, Smith C, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C et al. ( 2008 ) . The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy . HIV Medicine vol. 10 , ( 1 ) 35 - 43 .

Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M et al. ( 2008 ) . HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection . Journal of Virology vol. 83 , ( 3 ) 1228 - 1239 .

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al. ( 2008 ) . Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt's Lymphoma (BL) . Blood vol. 112 , ( 11 )

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH et al. ( 2008 ) . Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen . AIDS vol. 22 , ( 17 ) 2279 - 2289 .

Couto-Parada X, Lee A, Ushiro-Lumb I, Anderson J, Baily G, Limb S, Noble H, Orkin C et al. ( 2008 ) . Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification . Journal of the International AIDS Society vol. 11 , ( Suppl 1 )

Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT ( 2008 ) . The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United Kingdom . JAIDS Journal of Acquired Immune Deficiency Syndromes . vol. 49 , 196 - 204 .

Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA et al. ( 2008 ) . Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study . AIDS . vol. 22 , 1943 - 1950 .

Ladenheim D, Horn O, Werneke U, Phillpot M, Murungi A, Theobald N, Orkin C ( 2008 ) . Potential health risks of complementary alternative medicines in HIV patients . HIV Medicine vol. 9 , ( 8 ) 653 - 659 .

El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD et al. ( 2008 ) . Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial . Annals of Internal Medicine vol. 149 , ( 5 ) 289 - 299 .

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al. ( 2008 ) . Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication . Antiviral Therapy vol. 13 , ( 5 ) 675 - 685 .

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al. ( 2008 ) . CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S LYMPHOMA (BL) . HAEMATOLOGICA . vol. 93 , 393 - 393 .

Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H et al. ( 2008 ) . HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004 . The Pediatric Infectious Disease Journal vol. 27 , ( 5 ) 457 - 459 .

Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN ( 2008 ) . Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up . The Journal of Infectious Diseases vol. 197 , ( 8 ) 1145 - 1155 .

Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard P-M, Grund B et al. ( 2008 ) . Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study . The Journal of Infectious Diseases vol. 197 , ( 8 ) 1133 - 1144 .

Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J et al. ( 2008 ) . Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3 . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 47 , ( 2 ) 202 - 205 .

Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M et al. ( 2008 ) . Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? . AIDS vol. 22 , ( 3 ) 349 - 356 .

Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G et al. ( 2008 ) . Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK . HIV Medicine vol. 9 , ( 1 ) 47 - 56 .

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al. ( 2008 ) . CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S ILYMPHOMA (BL) . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 93 , 393 - 393 .

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al. ( 2008 ) . Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Assochited Burkitt's Lymphorna (BL) . BLOOD . vol. 112 , 1235 - 1236 .

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al. ( 2007 ) . Brief communication: rituximab in HIV-associated multicentric Castleman disease . Annals of Internal Medicine vol. 147 , ( 12 ) 836 - 839 .

Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T et al. ( 2007 ) . Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study . The Lancet vol. 370 , ( 9603 ) 1923 - 1928 .

Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M ( 2007 ) . Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease . Blood vol. 110 , ( 12 ) 4132 - 4133 .

( 2007 ) . HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 46 , ( 3 ) 275 - 278 .

Gupta RK, Loveday C, Kalidindi U, Lechelt M, Skinner C, Orkin C ( 2007 ) . Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice . International Journal of STD & AIDS vol. 18 , ( 9 ) 630 - 632 .

Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M et al. ( 2007 ) . Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count . AIDS vol. 21 , ( 13 ) 1717 - 1721 .

Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P et al. ( 2007 ) . Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures . AIDS vol. 21 , ( 11 ) 1423 - 1430 .

( 2007 ) . Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom . AIDS vol. 21 , ( 8 ) 1035 - 1039 .

Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P et al. ( 2007 ) . CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003 . HIV Medicine vol. 8 , ( 3 ) 135 - 141 .

Nolan D, Phillips E, Mallal S ( 2005 ) . Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance . Clinical Infectious Diseases vol. 42 , ( 3 ) 408 - 410 .

Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B ( 2005 ) . Estimating HIV-1 Drug Resistance in Antiretroviral-Treated Individuals in the United Kingdom . The Journal of Infectious Diseases . vol. 192 , 967 - 973 .

Beggs S, Sewell J, Efron D, Orkin C ( 2005 ) . Developmental assessment of children: A survey of Australian and New Zealand paediatricians . Journal of Paediatrics and Child Health vol. 41 , ( 8 ) 444 - 448 .

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G et al. ( 2005 ) . A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study) . Journal of Antimicrobial Chemotherapy vol. 55 , ( 2 ) 246 - 251 .

Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B ( 2004 ) . A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART) . Journal of Antimicrobial Chemotherapy vol. 53 , ( 3 ) 501 - 505 .

Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, Imami N, Gazzard BG ( 2003 ) . Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection . AIDS vol. 17 , ( 9 ) 1411 - 1413 .

Morlese J, Qazi N, Orkin C, Datta D, Abbas R, Gazzard B, Francis N, Moyle G ( 2002 ) . Both stavudine and zidovudine-based therapy is associated with gluteal subcutaneous adipocyte depletion . ANTIVIRAL THERAPY . vol. 7 , L22 - L22 .

Orkin C, Morlese J, Buckingham A, Gazzard B, Asboe D ( 2000 ) . Estimation of the prevalence of ΔF508 heterozygosity in HIV infected patients with <i>Pseudomonas aeruginosa</i> pulmonary infection . AIDS . vol. 14 , S133 - S133 .